NO971381D0 - Kombinasjon av prostacyklin med et östrogen eller progestin for forhindring og behandling av atherosklerotisk vaskulær sykdom, innbefattende preeklampsi, og for behandling av hypertensjon, og for hormonerstatningsterapi - Google Patents

Kombinasjon av prostacyklin med et östrogen eller progestin for forhindring og behandling av atherosklerotisk vaskulær sykdom, innbefattende preeklampsi, og for behandling av hypertensjon, og for hormonerstatningsterapi

Info

Publication number
NO971381D0
NO971381D0 NO971381A NO971381A NO971381D0 NO 971381 D0 NO971381 D0 NO 971381D0 NO 971381 A NO971381 A NO 971381A NO 971381 A NO971381 A NO 971381A NO 971381 D0 NO971381 D0 NO 971381D0
Authority
NO
Norway
Prior art keywords
treatment
progestin
prostacyclin
estrogen
hypertension
Prior art date
Application number
NO971381A
Other languages
English (en)
Other versions
NO971381L (no
Inventor
Robert E Garfield
Kristof Chwalisz
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO971381D0 publication Critical patent/NO971381D0/no
Publication of NO971381L publication Critical patent/NO971381L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO971381A 1994-09-22 1997-03-24 Kombinasjon av prostacyklin med et östrogen eller progestin for å hindre og behandle atherosklerotiske karsykdommer inkludert preeklampsi og for behandling av höyt blodtrykk, og for hormonerstatningsterapi NO971381L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/310,950 US6613757B1 (en) 1994-09-22 1994-09-22 Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy
PCT/US1995/012336 WO1996009826A2 (en) 1994-09-22 1995-09-22 Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy

Publications (2)

Publication Number Publication Date
NO971381D0 true NO971381D0 (no) 1997-03-24
NO971381L NO971381L (no) 1997-05-22

Family

ID=23204746

Family Applications (1)

Application Number Title Priority Date Filing Date
NO971381A NO971381L (no) 1994-09-22 1997-03-24 Kombinasjon av prostacyklin med et östrogen eller progestin for å hindre og behandle atherosklerotiske karsykdommer inkludert preeklampsi og for behandling av höyt blodtrykk, og for hormonerstatningsterapi

Country Status (16)

Country Link
US (1) US6613757B1 (no)
EP (1) EP0790827A2 (no)
JP (1) JPH10506899A (no)
AU (1) AU699699B2 (no)
BG (1) BG101349A (no)
BR (1) BR9509030A (no)
CA (1) CA2200858A1 (no)
CZ (1) CZ88997A3 (no)
HU (1) HUT76959A (no)
IL (1) IL115399A0 (no)
IS (1) IS4450A (no)
NO (1) NO971381L (no)
PL (1) PL319295A1 (no)
SK (1) SK38697A3 (no)
WO (1) WO1996009826A2 (no)
ZA (1) ZA958047B (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2754179B1 (fr) 1996-10-08 1998-12-24 Theramex Nouvelle composition hormononale et son utilisation
US6056972A (en) 1997-02-26 2000-05-02 Dimera, Llc Method for reducing coronary artery reactivity
US6602487B1 (en) 1997-02-26 2003-08-05 Dimera Incorporated Methods and tests for producing and for inhibiting coronary artery vasospasms
US20040167111A1 (en) * 1998-04-15 2004-08-26 Michael Oettel Pharmaceutical preparations for treating side effects during and/or after GnRHa therapy
US6844333B1 (en) * 1999-03-26 2005-01-18 The Trustees Of The University Of Pennsylvania Method of treating atherosclerosis
WO2001030356A1 (fr) 1999-10-25 2001-05-03 Laboratoire Theramex Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7335362B2 (en) * 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
US7435419B2 (en) * 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
US7572780B2 (en) 2003-01-21 2009-08-11 Dimera, Incorporated Method and kit for reducing the symptoms of peripheral vascular disease
SI1624878T1 (sl) * 2003-05-22 2007-02-28 Pantarhei Bioscience Bv Uporaba sestavkov, ki obsegajo estrogensko komponento, za zdravljenje in preprecevanje muskuloskeletne bolecine
WO2005110462A2 (en) 2004-05-04 2005-11-24 Children's Medical Center Corporation Methods and compositions for treatment of preeclampsia
EP1761231A1 (en) * 2004-06-07 2007-03-14 Duramed Pharmaceuticals, Inc. Dispenser for progestin used for acute and maintenance treatment of dub
MX2007003522A (es) 2004-09-24 2007-06-11 Beth Israel Hospital Complicaciones del embarazo.
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
UY33103A (es) * 2009-12-15 2011-07-29 Techsphere S A De C V Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3174542A4 (en) 2014-07-29 2018-01-03 TherapeuticsMD, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
BR112018070199A2 (pt) 2016-04-01 2019-01-29 Therapeuticsmd Inc composição farmacêutica de hormônio esteroide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4189795A (en) * 1978-09-20 1980-02-26 Conti Angelo J Toilet flush valve
US4879285A (en) * 1986-08-22 1989-11-07 Royal North Shore Hospital And Area Health Service Fertility control
US5895783A (en) * 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor

Also Published As

Publication number Publication date
IS4450A (is) 1997-03-21
WO1996009826A3 (en) 1996-05-23
SK38697A3 (en) 1998-05-06
WO1996009826A2 (en) 1996-04-04
CA2200858A1 (en) 1996-04-04
NO971381L (no) 1997-05-22
MX9702207A (es) 1998-05-31
AU3727595A (en) 1996-04-19
ZA958047B (en) 1996-12-20
JPH10506899A (ja) 1998-07-07
HUT76959A (hu) 1998-01-28
PL319295A1 (en) 1997-08-04
CZ88997A3 (cs) 1998-02-18
EP0790827A2 (en) 1997-08-27
BG101349A (en) 1998-03-31
BR9509030A (pt) 1997-11-25
US6613757B1 (en) 2003-09-02
IL115399A0 (en) 1995-12-31
AU699699B2 (en) 1998-12-10

Similar Documents

Publication Publication Date Title
NO971381D0 (no) Kombinasjon av prostacyklin med et östrogen eller progestin for forhindring og behandling av atherosklerotisk vaskulær sykdom, innbefattende preeklampsi, og for behandling av hypertensjon, og for hormonerstatningsterapi
FI971969A0 (fi) Peräpukamien hoitoon tarkoitettuja koostumuksia ja käyttömenetelmä
HK1042475A1 (zh) 用於治療炎癥的取代噻唑
NO992140L (no) Progesteron for behandling eller redusering av ischemi
AU3497295A (en) Compositions and methods for the treatment of body weight disorders, including obesity
AU3218197A (en) Natural progesterone for the treatment of side effects of progestins and progesterone analogues
HK1000697A1 (en) Use of droloxifene for the treatment of cardiovascular diseases
AU3548795A (en) Benzopyranopyrazolyl derivatives for the treatment of inflammation
AU6392496A (en) The combination of topical nasal antihistamines and topical nasal steroids
CA2069483A1 (en) Steroid sulphatase inhibitors
ZA965938B (en) Use of MP52 of MP121 for the treatment and prevention of diseases of the nervous system.
NO20014674D0 (no) Fremgangsmåte for behandling av neurologiske og neuropsykiatriske forstyrrelser
World Health Organization Guidelines for the primary prevention of mental, neurological and psychosocial disorders. 5. Staff burnout
IL120558A0 (en) New hormonal medicaments and their use for the correction of oestrogenic deficiencies
EP1039883A4 (en) METHOD FOR TREATING APOLIPOPROTEIN E CONDITIONAL DISEASES
AU1104392A (en) Method for the treatment of hepatic failure and disease
AU7484596A (en) Combination therapy for the treatment of diabetes and obesity
IL129622A0 (en) Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
EP0689839A3 (en) Use of adenosine triphosphatase inhibitors for the manufacture of a medicament for the treatment of beta-amyloid peptide-associated disorders
EP0981357A4 (en) METHODS AND COMPOSITIONS APPLICABLE TO THE DIAGNOSIS AND TREATMENT OF NEUROPSYCHIATRIC DISORDERS
IL129624A0 (en) Novel (+)-enantiomers of CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
IL129623A0 (en) Novel trans-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
AU5558498A (en) Bmp-4 promoter and use thereof in screening of therapeutic agents for the prevention and/or treatment of osteoporosis
IL129618A0 (en) Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
DE59708511D1 (de) Verwendung von 7-(1-aminomethyl-2-oxa-7-aza-bicyclo 3.3.0]oct-7-yl)-chinoloncarbonsäure- und -naphthyridoncarbonsäure-derivaten zur therapie von helicobacter-pylori-infektionen und den damit assoziierten gastroduodenalen erkrankungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application